Meril Life Sciences has unveiled MyClip, India’s first Transcatheter Edge-to-Edge Repair (TEER) system for severe Mitral Regurgitation (MR), marking a historic leap in cardiac treatment innovation. The system was launched during the Structural Heart Innovation event held from June 13–15 at Meril Academy in Vapi, where over 150 top Indian cardiologists joined global experts including Prof. Ottavio Alfieri, Prof. Francesco Maisano, and Prof. Agricola.
MyClip is designed for high-risk patients suffering from severe MR—many of whom are ineligible for open-heart surgery due to age, diabetes, hypertension, or organ-related issues. The minimally invasive procedure takes about an hour, with most patients discharged in 3–5 days and resuming normal activities shortly after.
Backed by the COAPT Study, TEER has proven to significantly lower heart failure hospitalizations and mortality compared to standard therapies. Despite only 150 TEER procedures being performed annually in India, early adoption signals growing demand among younger patients aged 30–60.
In Kolkata, cardiac specialists welcomed the launch, highlighting a sharp increase in young MR patients in urban hospitals. They expect MyClip to bridge the current treatment gap and reduce surgical burden. Sanjeev Bhatt of Meril emphasized MyClip as a turning point in Indian medtech, supported by a national awareness drive featuring MS Dhoni under the #TreatmentZarooriHai campaign.